Showing 8141-8150 of 9757 results for "".
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-t
- The HydraFacial Company And Circadia Expand Partner Boosters Globallyhttps://practicaldermatology.com/news/the-hydrafacial-company-and-circadia-expand-partner-boosters-globally/2460579/The HydraFacial Company is extending their partnership with Circadia to offer the Chrono-Peptide Booster and ProTec Plus Booster to HydraFacial providers in more than 40 countries. "The Circadia boosters for HydraFacial are already loved by providers and consume
- Vyne Therapeutics Announces Covered Status for Zilxi with Express Scriptshttps://practicaldermatology.com/news/yne-therapeutics-announces-covered-status-for-zilxi-with-express-scripts/2460557/Vyne Therapeutics Inc.’s Zilxi (minocycline) will be covered on Express Scripts' National Preferred, Flex, and Basic commercial formularies effective O
- Brickell Biotech Initiates Phase 3 Trial of Sofpironium Bromide Gel for Hyperhidrosishttps://practicaldermatology.com/news/brickell-biotech-initiates-phase-3-trial-of-sofpironium-bromide-gel-for-hyperhidrosis/2460554/Brickell Biotech, Inc. has initiated its first pivotal US Phase 3 clinical study evaluating sofpironium bromide gel, 15% as a potential treatment for primary axillary hyperhidrosis (“Cardigan I Study”). “This continues to be an exciting time for Brickell, with initiati
- TARGET-DERM Real-World Study Expandshttps://practicaldermatology.com/news/target-derm-real-world-study-expands/2460550/Target RWE is expanding its active longitudinal dermatology registry, TARGET-DERM (
- Drumroll, Please...Gwyneth Paltrow Named Global Face of Xeominhttps://practicaldermatology.com/news/gwyneth-paltrow-named-global-face-of-xeomin/2460530/Actress and Goop wellness guru Gwyneth Paltrow is the first global face of Merz Aesthetics' Xeomin. In this role, Paltrow will be sharing details about what she does to look and feel her best, and will ask women to do the same on social media using #DareToSelfCare. “
- Remembering 9-11: A Dermatology Perspectivehttps://practicaldermatology.com/news/remembering-9-11-a-dermatology-perspective/2460522/New research takes a close look at dermatologic injuries and chronic skin conditions that have affected survivors and responders during the nearly two decades since the terrorist attacks on September 11, 2001. These chronic illnesses include sarcoidosis, autoimmune disease, ill-defined
- Actress Sarah Michelle Gellar Is CoolSculpting’s New International Ambassadorhttps://practicaldermatology.com/news/actress-sarah-michelle-gellar-is-coolsculptings-new-international-ambassador/2460518/
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- MC2 Partners with EPI for Commercialization of Wynzorahttps://practicaldermatology.com/news/mc2-partners-partners-with-epi-for-commercialization-of-wynzora/2460510/MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) in the US. Wynzora Cream was approvedby the FDA last month for the topical treatment of plaque psoriasis in adult